{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:05:25Z","timestamp":1789175125222,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003074","name":"Ministry of Science, Technology and Productive Innovation, Argentina | Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["Fonarsec 0004\/2021"],"award-info":[{"award-number":["Fonarsec 0004\/2021"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003074","name":"Ministry of Science, Technology and Productive Innovation, Argentina | Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["PICT-O-2021\/00008"],"award-info":[{"award-number":["PICT-O-2021\/00008"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003074","name":"Ministry of Science, Technology and Productive Innovation, Argentina | Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["PICT-O-2021\/00008"],"award-info":[{"award-number":["PICT-O-2021\/00008"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>COVID-19 vaccines were originally designed based on the ancestral Spike protein, but immune escape of emergent Variants of Concern (VOC) jeopardized their efficacy, warranting variant-proof vaccines. Here, we used preclinical rodent models to establish the cross-protective and cross-neutralizing capacity of adenoviral-vectored vaccines expressing VOC-matched Spike. CoroVaxG.3-D.FR, matched to Delta Plus Spike, displayed the highest levels of nAb to the matched VOC and mismatched variants. Cross-protection against viral infection in aged K18-hACE2 mice showed dramatic differences among the different vaccines. While Delta-targeted vaccines fully protected mice from a challenge with Gamma, a Gamma-based vaccine offered only partial protection to Delta challenge. Administration of CorovaxG.3-D.FR in a prime\/boost regimen showed that a booster was able to increase the neutralizing capacity of the sera against all variants and fully protect aged K18-hACE2 mice against Omicron BA.1, as a BA.1-targeted vaccine did. The neutralizing capacity of the sera diminished in all cases against Omicron BA.2 and BA.5. Altogether, the data demonstrate that a booster with a vaccine based on an antigenically distant variant, such as Delta or BA.1, has the potential to protect from a wider range of SARS-CoV-2 lineages, although careful surveillance of breakthrough infections will help to evaluate combination vaccines targeting antigenically divergent variants yet to emerge.<\/jats:p>","DOI":"10.1038\/s41541-023-00737-4","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T09:02:54Z","timestamp":1696410174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cross-protection and cross-neutralization capacity of ancestral and VOC-matched SARS-CoV-2 adenoviral vector-based vaccines"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1330-9125","authenticated-orcid":false,"given":"Sabrina E.","family":"Vinz\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda V.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5089-3757","authenticated-orcid":false,"given":"Eduardo G. A.","family":"Cafferata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna S.","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6944-7896","authenticated-orcid":false,"given":"Paula M.","family":"Berguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonora","family":"Nusblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea V.","family":"Pontoriero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1450-6382","authenticated-orcid":false,"given":"Eduardo M.","family":"Belotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia R.","family":"Salvetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3061-0590","authenticated-orcid":false,"given":"Diego L.","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel E.","family":"Vilardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin M.","family":"Avaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara L.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda E.","family":"Dattero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Carobene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0112-5641","authenticated-orcid":false,"given":"Maximiliano","family":"S\u00e1nchez-Lamas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimena","family":"Afonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Heitrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9057-511X","authenticated-orcid":false,"given":"Alejandro E.","family":"Crist\u00f3falo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5448-5483","authenticated-orcid":false,"given":"Lisandro H.","family":"Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa G.","family":"Baumeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7663-3133","authenticated-orcid":false,"given":"Hugo H.","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Edelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6512-8553","authenticated-orcid":false,"given":"Osvaldo L.","family":"Podhajcer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,4]]},"reference":[{"key":"737_CR1","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","volume":"22","author":"OJ Watson","year":"2022","unstructured":"Watson, O. J. et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect. Dis. 22, 1293\u20131302 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"737_CR2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.15585\/mmwr.mm7104e2","volume":"71","author":"AG Johnson","year":"2022","unstructured":"Johnson, A. G. et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence - 25 U.S. Jurisdictions, April 4-December 25, 2021. MMWR Morb. Mortal. Wkly Rep. 71, 132\u2013138 (2022).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"737_CR3","doi-asserted-by":"crossref","first-page":"e2310650","DOI":"10.1001\/jamanetworkopen.2023.10650","volume":"6","author":"F Menegale","year":"2023","unstructured":"Menegale, F. et al. Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-analysis. JAMA Netw. open 6, e2310650 (2023).","journal-title":"JAMA Netw. open"},{"key":"737_CR4","unstructured":"WHO. SAGE updates COVID-19 vaccination guidance, https:\/\/www.who.int\/news\/item\/28-03-2023-sage-updates-covid-19-vaccination-guidance (2023)."},{"key":"737_CR5","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S1473-3099(22)00801-5","volume":"23","author":"N Bobrovitz","year":"2023","unstructured":"Bobrovitz, N. et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect. Dis. 23, 556\u2013567 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"737_CR6","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S1473-3099(22)00746-0","volume":"22","author":"The Lancet Infectious D.","year":"2022","unstructured":"The Lancet Infectious D. Why hybrid immunity is so triggering. Lancet Infect. Dis. 22, 1649 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"737_CR7","unstructured":"UNDP. Global Dashboard for Vaccine Equity, https:\/\/data.undp.org\/vaccine-equity\/ (2023)."},{"key":"737_CR8","unstructured":"WHO. WHO Coronavirus (COVID-19) Dashboard. World Health Organizaton (WHO) (2023)."},{"key":"737_CR9","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","volume":"182","author":"B Korber","year":"2020","unstructured":"Korber, B. et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell 182, 812\u2013827.e819 (2020).","journal-title":"Cell"},{"key":"737_CR10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70827-z","volume":"10","author":"S Isabel","year":"2020","unstructured":"Isabel, S. et al. Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide. Sci. Rep. 10, 14031 (2020).","journal-title":"Sci. Rep."},{"key":"737_CR11","unstructured":"Tracking SARS-CoV-2 variants, https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants\/. World Health Organization (WHO)."},{"key":"737_CR12","doi-asserted-by":"crossref","first-page":"100991","DOI":"10.1016\/j.xcrm.2023.100991","volume":"4","author":"Q He","year":"2023","unstructured":"He, Q. et al. An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB. Cell Rep. Med. 4, 100991 (2023).","journal-title":"Cell Rep. Med."},{"key":"737_CR13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bbrc.2021.11.059","volume":"586","author":"DA Ostrov","year":"2022","unstructured":"Ostrov, D. A. & Knox, G. W. Emerging mutation patterns in SARS-CoV-2 variants. Biochem. biophys. Res. Commun. 586, 87\u201392 (2022).","journal-title":"Biochem. biophys. Res. Commun."},{"key":"737_CR14","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41591-021-01548-7","volume":"27","author":"KB Pouwels","year":"2021","unstructured":"Pouwels, K. B. et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat. Med. 27, 2127\u20132135 (2021).","journal-title":"Nat. Med."},{"key":"737_CR15","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","volume":"602","author":"D Planas","year":"2022","unstructured":"Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671\u2013675 (2022).","journal-title":"Nature"},{"key":"737_CR16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41577-021-00662-4","volume":"22","author":"M Lipsitch","year":"2022","unstructured":"Lipsitch, M., Krammer, F., Regev-Yochay, G., Lustig, Y. & Balicer, R. D. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat. Rev. Immunol. 22, 57\u201365 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"737_CR17","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.chom.2021.02.020","volume":"29","author":"JA Plante","year":"2021","unstructured":"Plante, J. A. et al. The variant gambit: COVID-19\u2019s next move. Cell Host Microbe 29, 508\u2013515 (2021).","journal-title":"Cell Host Microbe"},{"key":"737_CR18","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/s41591-022-01911-2","volume":"28","author":"H Tegally","year":"2022","unstructured":"Tegally, H. et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat. Med. 28, 1785\u20131790 (2022).","journal-title":"Nat. Med."},{"key":"737_CR19","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3390\/vaccines10060864","volume":"10","author":"GI Lopez-Cortes","year":"2022","unstructured":"Lopez-Cortes, G. I. et al. The Spike Protein of SARS-CoV-2 Is Adapting Because of Selective Pressures. Vaccines (Basel) 10, 864 (2022).","journal-title":"Vaccines (Basel)"},{"key":"737_CR20","doi-asserted-by":"crossref","first-page":"781429","DOI":"10.3389\/fcimb.2021.781429","volume":"11","author":"SM Hirabara","year":"2021","unstructured":"Hirabara, S. M. et al. SARS-COV-2 Variants: Differences and Potential of Immune Evasion. Front. Cell. Infect. Microbiol. 11, 781429 (2021).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"737_CR21","doi-asserted-by":"crossref","first-page":"e0055822","DOI":"10.1128\/jvi.00558-22","volume":"96","author":"T Moyo-Gwete","year":"2022","unstructured":"Moyo-Gwete, T. et al. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants. J. Virol. 96, e0055822 (2022).","journal-title":"J. Virol."},{"key":"737_CR22","unstructured":"Wilks S. H., et al. Mapping SARS-CoV-2 antigenic relationships and serological responses. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2022.01.28.477987v3 (2023)."},{"key":"737_CR23","doi-asserted-by":"crossref","first-page":"e1010248","DOI":"10.1371\/journal.ppat.1010248","volume":"18","author":"AJ Greaney","year":"2022","unstructured":"Greaney, A. J. et al. A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. PLoS Pathog. 18, e1010248 (2022).","journal-title":"PLoS Pathog."},{"key":"737_CR24","doi-asserted-by":"crossref","first-page":"e0164722","DOI":"10.1128\/mbio.01647-22","volume":"13","author":"KA Bowman","year":"2022","unstructured":"Bowman, K. A. et al. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity. mBio 13, e0164722 (2022).","journal-title":"mBio"},{"key":"737_CR25","doi-asserted-by":"crossref","unstructured":"Faulkner N., et al. Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains. Elife 10, (2021).","DOI":"10.7554\/eLife.69317"},{"key":"737_CR26","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41586-023-05715-3","volume":"615","author":"A Schiepers","year":"2023","unstructured":"Schiepers, A. et al. Molecular fate-mapping of serum antibody responses to repeat immunization. Nature 615, 482\u2013489 (2023).","journal-title":"Nature"},{"key":"737_CR27","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.abh1139","volume":"373","author":"M Yuan","year":"2021","unstructured":"Yuan, M. et al. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Sci. (N. Y., NY) 373, 818\u2013823 (2021).","journal-title":"Sci. (N. Y., NY)"},{"key":"737_CR28","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3390\/vaccines9101106","volume":"9","author":"MV Lopez","year":"2021","unstructured":"Lopez, M. V. et al. A Single Dose of a Hybrid hAdV5-Based Anti-COVID-19 Vaccine Induces a Long-Lasting Immune Response and Broad Coverage against VOC. Vaccines (Basel) 9, 1106 (2021).","journal-title":"Vaccines (Basel)"},{"key":"737_CR29","doi-asserted-by":"crossref","unstructured":"Olmedillas E. et al. Structure-based design of a highly stable, covalently-linked SARS-CoV-2 spike trimer with improved structural properties and immunogenicity. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2021.05.06.441046v1 (2021).","DOI":"10.1101\/2021.05.06.441046"},{"key":"737_CR30","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32262-8","volume":"13","author":"D Mannar","year":"2022","unstructured":"Mannar, D. et al. SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization. Nat. Commun. 13, 4696 (2022).","journal-title":"Nat. Commun."},{"key":"737_CR31","doi-asserted-by":"crossref","first-page":"105370","DOI":"10.1016\/j.antiviral.2022.105370","volume":"204","author":"C Seephetdee","year":"2022","unstructured":"Seephetdee, C. et al. A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera. Antivir. Res 204, 105370 (2022).","journal-title":"Antivir. Res"},{"key":"737_CR32","doi-asserted-by":"crossref","first-page":"e0020321","DOI":"10.1128\/JVI.00203-21","volume":"95","author":"GW Carnell","year":"2021","unstructured":"Carnell, G. W. et al. SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses. J. Virol. 95, e0020321 (2021).","journal-title":"J. Virol."},{"key":"737_CR33","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19883-7","volume":"11","author":"S Alexandersen","year":"2020","unstructured":"Alexandersen, S., Chamings, A. & Bhatta, T. R. SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication. Nat. Commun. 11, 6059 (2020).","journal-title":"Nat. Commun."},{"key":"737_CR34","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41586-022-04441-6","volume":"603","author":"PJ Halfmann","year":"2022","unstructured":"Halfmann, P. J. et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603, 687\u2013692 (2022).","journal-title":"Nature"},{"key":"737_CR35","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/d41586-021-00340-4","volume":"590","author":"DR Burton","year":"2021","unstructured":"Burton, D. R. & Topol, E. J. Variant-proof vaccines - invest now for the next pandemic. Nature 590, 386\u2013388 (2021).","journal-title":"Nature"},{"key":"737_CR36","volume":"5","author":"R Bos","year":"2020","unstructured":"Bos, R. et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vacc. 5, 91 (2020).","journal-title":"NPJ Vacc."},{"key":"737_CR37","doi-asserted-by":"crossref","unstructured":"Amanat F., et al. Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model. mBio 12, (2021).","DOI":"10.1128\/mBio.02648-20"},{"key":"737_CR38","doi-asserted-by":"crossref","first-page":"e3001384","DOI":"10.1371\/journal.pbio.3001384","volume":"19","author":"F Amanat","year":"2021","unstructured":"Amanat, F. et al. Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus. PLoS Biol. 19, e3001384 (2021).","journal-title":"PLoS Biol."},{"key":"737_CR39","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31556-1","volume":"13","author":"M Bekliz","year":"2022","unstructured":"Bekliz, M. et al. Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs. Nat. Commun. 13, 3840 (2022).","journal-title":"Nat. Commun."},{"key":"737_CR40","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1016\/j.cell.2021.06.020","volume":"184","author":"C Liu","year":"2021","unstructured":"Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220\u20134236.e4213 (2021).","journal-title":"Cell"},{"key":"737_CR41","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.immuni.2022.07.018","volume":"55","author":"K van der Straten","year":"2022","unstructured":"van der Straten, K. et al. Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron. Immunity 55, 1725\u20131731.e1724 (2022).","journal-title":"Immunity"},{"key":"737_CR42","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41392-022-01137-1","volume":"7","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Cross-neutralization and cross-protection among SARS-CoV-2 viruses bearing different variant spikes. Signal Transduct. Target. Ther. 7, 285 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"737_CR43","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1126\/science.abm5835","volume":"375","author":"SM Reincke","year":"2022","unstructured":"Reincke, S. M. et al. SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies. Sci. (N. Y., NY) 375, 782\u2013787 (2022).","journal-title":"Sci. (N. Y., NY)"},{"key":"737_CR44","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1038\/s41467-023-41049-4","volume":"14","author":"A Roessler","year":"2023","unstructured":"Roessler, A. et al. Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography. Nat. Commun. 14, 5224 (2023).","journal-title":"Nat. Commun."},{"key":"737_CR45","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1016\/S2666-5247(22)00384-6","volume":"4","author":"AZ Mykytyn","year":"2023","unstructured":"Mykytyn, A. Z. et al. Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1. Lancet Microbe 4, e294\u2013e295 (2023).","journal-title":"Lancet Microbe"},{"key":"737_CR46","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","volume":"186","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 186, 279\u2013286.e278 (2023).","journal-title":"Cell"},{"key":"737_CR47","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-35312-3","volume":"13","author":"A Rossler","year":"2022","unstructured":"Rossler, A. et al. BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants. Nat. Commun. 13, 7701 (2022).","journal-title":"Nat. Commun."},{"key":"737_CR48","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","volume":"185","author":"A Tuekprakhon","year":"2022","unstructured":"Tuekprakhon, A. et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 185, 2422\u20132433.e2413 (2022).","journal-title":"Cell"},{"key":"737_CR49","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","volume":"608","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 608, 593\u2013602 (2022).","journal-title":"Nature"},{"key":"737_CR50","volume":"13","author":"K Khan","year":"2022","unstructured":"Khan, K. et al. Omicron BA.4\/BA.5 escape neutralizing immunity elicited by BA.1 infection. Nat. Commun. 13, 4686 (2022).","journal-title":"Nat. Commun."},{"key":"737_CR51","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/d41586-022-02806-5","volume":"609","author":"E Callaway","year":"2022","unstructured":"Callaway, E. New Omicron-specific vaccines offer similar protection to existing boosters. Nature 609, 232\u2013233 (2022).","journal-title":"Nature"},{"key":"737_CR52","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41591-023-02228-4","volume":"29","author":"DS Khoury","year":"2023","unstructured":"Khoury, D. S. et al. Predicting the efficacy of variant-modified COVID-19 vaccine boosters. Nat. Med. 29, 574\u2013578 (2023).","journal-title":"Nat. Med."},{"key":"737_CR53","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.chom.2022.10.012","volume":"30","author":"W Wang","year":"2022","unstructured":"Wang, W. et al. Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history. Cell Host Microbe 30, 1745\u20131758.e1747 (2022).","journal-title":"Cell Host Microbe"},{"key":"737_CR54","doi-asserted-by":"crossref","first-page":"100510","DOI":"10.1016\/j.xcrm.2022.100510","volume":"3","author":"SI Richardson","year":"2022","unstructured":"Richardson, S. I. et al. SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity. Cell Rep. Med. 3, 100510 (2022).","journal-title":"Cell Rep. Med."},{"key":"737_CR55","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.chom.2022.03.029","volume":"30","author":"SI Richardson","year":"2022","unstructured":"Richardson, S. I. et al. SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals. Cell Host Microbe 30, 880\u2013886.e884 (2022).","journal-title":"Cell Host Microbe"},{"key":"737_CR56","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.cell.2022.03.037","volume":"185","author":"B Ying","year":"2022","unstructured":"Ying, B. et al. Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. Cell 185, 1572\u20131587.e1511 (2022).","journal-title":"Cell"},{"key":"737_CR57","volume":"29","author":"IJ Lee","year":"2022","unstructured":"Lee, I. J. et al. A booster dose of Delta x Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants. J. Biomed. Sci. 29, 49 (2022).","journal-title":"J. Biomed. Sci."},{"key":"737_CR58","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","volume":"185","author":"L Qu","year":"2022","unstructured":"Qu, L. et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell 185, 1728\u20131744.e1716 (2022).","journal-title":"Cell"},{"key":"737_CR59","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41586-022-04865-0","volume":"607","author":"RK Suryawanshi","year":"2022","unstructured":"Suryawanshi, R. K. et al. Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination. Nature 607, 351\u2013355 (2022).","journal-title":"Nature"},{"key":"737_CR60","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41592-023-01769-3","volume":"20","author":"K Gangavarapu","year":"2023","unstructured":"Gangavarapu, K. et al. Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations. Nat. Methods 20, 512\u2013522 (2023).","journal-title":"Nat. Methods"},{"key":"737_CR61","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nmeth.1318","volume":"6","author":"DG Gibson","year":"2009","unstructured":"Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6, 343\u2013345 (2009).","journal-title":"Nat. Methods"},{"key":"737_CR62","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41586-020-2943-z","volume":"589","author":"J Zheng","year":"2021","unstructured":"Zheng, J. et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature 589, 603\u2013607 (2021).","journal-title":"Nature"},{"key":"737_CR63","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19891-7","volume":"11","author":"FS Oladunni","year":"2020","unstructured":"Oladunni, F. S. et al. Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat. Commun. 11, 6122 (2020).","journal-title":"Nat. Commun."},{"key":"737_CR64","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/JVI.02012-06","volume":"81","author":"PB McCray Jr.","year":"2007","unstructured":"McCray, P. B. Jr. et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 81, 813\u2013821 (2007).","journal-title":"J. Virol."},{"key":"737_CR65","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1038\/s41596-020-0394-5","volume":"15","author":"J Nie","year":"2020","unstructured":"Nie, J. et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat. Protoc. 15, 3699\u20133715 (2020).","journal-title":"Nat. Protoc."},{"key":"737_CR66","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1126\/science.1256427","volume":"346","author":"JM Fonville","year":"2014","unstructured":"Fonville, J. M. et al. Antibody landscapes after influenza virus infection or vaccination. Sci. (N. Y., NY) 346, 996\u20131000 (2014).","journal-title":"Sci. (N. Y., NY)"},{"key":"737_CR67","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1126\/science.1097211","volume":"305","author":"DJ Smith","year":"2004","unstructured":"Smith, D. J. et al. Mapping the antigenic and genetic evolution of influenza virus. Sci. (N. Y., NY) 305, 371\u2013376 (2004).","journal-title":"Sci. (N. Y., NY)"},{"key":"737_CR68","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1016\/j.vaccine.2014.02.014","volume":"32","author":"IG Barr","year":"2014","unstructured":"Barr, I. G. et al. WHO recommendations for the viruses used in the 2013-2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013. Vaccine 32, 4713\u20134725 (2014).","journal-title":"Vaccine"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00737-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00737-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00737-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T11:14:06Z","timestamp":1700306046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00737-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,4]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["737"],"URL":"https:\/\/doi.org\/10.1038\/s41541-023-00737-4","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,4]]},"assertion":[{"value":"16 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.E.V., M.V.L., E.G.A.C. and O.L.P. are co-inventors of a related vaccine patent assigned to Fundaci\u00f3n Instituto Leloir and CONICET (USPTO Provisional Application # 63230284). M.S.L. is a consultant of Securitas Biosciences at Vaxinz Inc. The rest of the authors declare no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}